Evidence map›Paper›PMID 40600080›Full record

ArticleCureus2025

Differential Pregnancy Decisions in a Woman With a Recurrent Prenatal Diagnosis of Hypophosphatasia.

Taiyo Oguro, Ryuhei Nagai, Yuta Shimomoto

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taiyo OguroObstetrics and Gynecology, Kochi Medical School, Kochi, JPN.
Ryuhei NagaiObstetrics and Gynecology, Kochi Medical School, Kochi, JPN.
Yuta ShimomotoObstetrics and Gynecology, Kochi Medical School, Kochi, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypophosphatasia (HPP) is a rare inherited bone disorder caused by ALPL gene mutations, leading to reduced alkaline phosphatase (ALP) activity and impaired bone mineralization. Although its prevalence is relatively higher in Japan, prenatal diagnosis remains challenging. In particular, obstetricians and clinical geneticists, who are typically involved in prenatal assessment, often have limited experience with this condition due to its rarity. Among the various types of HPP, the prenatal benign form has a favorable prognosis, yet awareness and understanding of this specific subtype are limited. We report a case involving two separate pregnancies in the same woman, both diagnosed prenatally with HPP. During the second pregnancy, counseling was provided at 21 weeks by a physician. Given the rarity of HPP, even specialists such as obstetricians, pediatricians, or clinical geneticists often have limited direct clinical experience with the condition. Consequently, the counseling leaned toward a negative outlook, and the patient opted for termination. In contrast, during the third pregnancy, counseling began at nine weeks with detailed and balanced information, informed by the previous case and supported by a multidisciplinary team. This time, the patient elected to continue the pregnancy. The neonate was diagnosed with prenatal benign HPP and showed favorable clinical progress. This case highlights how the timing, quality, and balance of prenatal counseling can significantly influence parental decision-making in pregnancies complicated by rare diseases. In cases of rare conditions such as HPP, early and accurate counseling by an experienced multidisciplinary team is essential to support informed and autonomous decisions.

Indexed as

decision-making processgenetic counselinghypophosphatasiaprenatal diagnosisrare disease

Identifiers

PMID40600080
PMCPMC12212621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.